Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2021-04-16 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the use of part of its idle funds for cash management through low-risk financial products. It details the purpose, amount, risk controls, and approvals by the board and supervisory committee. The document is a formal announcement of a financing or capital management activity, specifically about the company's cash management and investment of idle funds. It does not contain financial statements or detailed financial results, nor is it a report or transcript. It is not a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities related to cash management and investment of idle funds.
2021-04-16 Chinese
2021年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第一季度报告' which translates to '2021 First Quarter Report'. It contains detailed financial data including balance sheet items, income statement items, cash flow statement items, and explanations of significant changes compared to prior periods. The document is about 6,130 characters long, which is sufficient to contain substantive financial data rather than just an announcement. It explicitly states it is a quarterly report and includes unaudited financial statements and management explanations. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-16 Chinese
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (auditor) for the company for the next fiscal year. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and independent directors. It does not contain actual financial statements or audit reports but rather the company's announcement about the auditor appointment to be approved at the upcoming shareholders' meeting. The document length is 3277 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits the category of an Audit Report / Information announcement, specifically about auditor appointment, which is best classified under 'Audit Report / Information' (AR). FY 2020
2021-04-16 Chinese
关于公司及全资子公司向银行申请2021年度综合授信额度及提供相应担保事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the company's and its wholly-owned subsidiaries' application for a comprehensive credit line and provision of corresponding guarantees for the year 2021. It details the credit amounts, guarantee amounts, authorization for legal representatives to handle related procedures, and financial data of the subsidiaries. The document is a formal announcement about financing activities and guarantees, not a financial report or audit. It does not contain financial statements or detailed financial analysis but rather informs about capital/financing updates and related board approvals. The document length is about 2610 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-04-16 Chinese
非经营性资金占用及其他关联资金往来情况的专项审计说明
Regulatory Filings
2021-04-16 Chinese
关于控股股东通过大宗交易方式减持超过1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a controlling shareholder reducing their stake by more than 1% through block trades. It details the shareholding changes, dates, and confirms no change in control or impact on operations. It is a typical major shareholding notification, reporting a significant change in ownership percentage. The document is short (1547 characters) and focused on shareholding changes, not a full financial report or earnings release. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2021-03-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.